Oral drug LP-118 for relapsed blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This Phase 1 study tests an oral (by mouth) drug called LP-118 in people whose blood cancers have returned or did not respond to prior treatment. The goal is to find a safe dose and see whether it can shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older (or age 13–18 for specific ALL situations with at least 40 kg weight)
- Have an advanced relapsed or refractory blood cancer such as CLL/SLL, NHL, multiple myeloma, AML, or related types
- Have had at least one or two prior treatments, depending on your specific cancer type
- Be able to swallow and absorb oral medicine and understand/sign consent
- Have adequate blood counts, kidney/liver function, and heart function based on screening tests
- Use reliable birth control during the study and for 90 days after stopping study drug
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a low-intensity bone marrow/stem cell transplant using a matched donor plus two medicines to help prevent the donor cells from attacking you. It aims to treat certain blood cancers—especially when standard treatment has not fully worked or when you are in remission but at higher risk.
This trial tests a new drug called PLM-102 in adults whose acute myeloid leukemia (a serious blood cancer) has come back or stopped responding to standard treatment. The goal is to see if PLM-102 can help patients whose cancer has proven difficult to control.
This trial tests a new combination of drugs (LP-118, ponatinib, vincristine, and dexamethasone) for people with T-cell leukemia or lymphoma that has returned or not responded to prior treatments. The goal is to see if this combination can help control the disease.
This Phase 1 trial studies LP-168 taken by mouth in people whose B-cell cancers have come back or did not respond to treatment. The study aims to find how the drug works, the right dose, and what side effects to expect.
This Phase 1 study tests whether an oral medicine called LP-168 can be given safely and possibly work against lymphoma that has come back or is not responding to standard treatment. It’s mainly looking for safety, but your results could help determine whether the drug should be studied further.
This trial tests a new combination of four drugs (LP-118, ponatinib, dexamethasone, and blinatumomab) to treat a specific type of blood cancer called Philadelphia-chromosome positive acute lymphoblastic leukemia (ALL). The study aims to see if this combination is safe and effective in newly diagnosed adults.
Hear when a new Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.